EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373)

Aifa precisa, vaccino AstraZeneca preferibile per under 55

EMA starts rolling review of REGN-COV2 antibody combination (casirivimab / imdevimab)

EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU

First COVID-19 vaccine safety update published

Clarification of Comirnaty dosage interval

Study on monoclonal antibodies for COVID-19: AIFA extends the terms of the call

AIFA call for a clinical study on efficacy of monoclonal antibodies for COVID-19 treatment

ICMRA statement on vaccines and regulatory processes

AIFA promotes a randomized clinical trial to assess the effectiveness of monoclonal antibodies

Aggiornamento: Estensione automatica della scadenza dei certificati GMP durante la pandemia da COVID-19 (15/01/2021)

AIFA publishes the COVID-19 vaccines FAQS on Pharmacovigilance

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca

Extra dose from vials of Comirnaty COVID-19 vaccine

COVID-19: AIFA authorizes Moderna vaccine

EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU

Report on COVID-19 vaccines

Update on rolling review of AstraZeneca’s COVID-19 vaccine

Procedure for submitting applications for marketing vaccines (State control for each batch) for COVID-19

AIFA, at least 6 doses can be obtained from each vial of BioNTech/Pfizer vaccine